Analyst Ratings For Avrobio Inc (NASDAQ:AVRO)
Today, HC Wainwright reiterated its Buy rating on Avrobio Inc (NASDAQ:AVRO) with a price target of $40.00.
There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Avrobio Inc (NASDAQ:AVRO) is Buy with a consensus target price of $39.50 per share, a potential 57.18% upside.
Some recent analyst ratings include
- 10/2/2018-Avrobio Inc (NASDAQ:AVRO) had its Buy rating reiterated by HC Wainwright with a $40.00 price target
- 7/16/2018-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Outperform rating and $40.00 price target
- 7/16/2018-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Outperform rating
- 7/16/2018-Avrobio Inc (NASDAQ:AVRO) has coverage initiated with a Outperform rating and $38.00 price target
About Avrobio Inc (NASDAQ:AVRO)
AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. Its lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease. The company is also developing AVR-RD-02 for the treatment of type 1 gaucher disease; AVR-RD-03 for the treatment of pompe disease; and AVR-RD-04 for the treatment of cystinosis. AVROBIO, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for Avrobio Inc (NASDAQ:AVRO)
Shares of Avrobio Inc closed the previous trading session at 25,13 −26,74 51,55 % with 35 shares trading hands.